Epclusa vs Harvoni
Side-by-side cost comparison based on Medicare Part D data
Epclusa
Sofosbuvir/Velpatasvir
Manufactured by Gilead
Harvoni
Ledipasvir/Sofosbuvir
Manufactured by Gilead
Harvoni costs 5% less per claim than Epclusa ($24,958.00 vs $26,143.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Epclusa | Harvoni |
|---|---|---|
| Avg Cost Per Claim | $26,143.00 | $24,958.00 |
| Total Medicare Spending | $1.1B | $1.2B |
| Total Beneficiaries | 10,000 | 12,000 |
| Total Claims | 42,000 | 48,000 |
| Annual Cost/Patient | $109,800.00 | $99,833.00 |
| Year-over-Year Change | -15.7% | -38.2% |
| Generic Available | Yes | No |
| Patent Expiration | Jan 31, 2023 | Oct 10, 2030 |
| Manufacturer | Gilead | Gilead |
| Condition | Hepatitis C | Hepatitis C |
| Generic Name | Sofosbuvir/Velpatasvir | Ledipasvir/Sofosbuvir |
Epclusa vs Harvoni: What the Data Shows
Epclusa (Sofosbuvir/Velpatasvir) and Harvoni (Ledipasvir/Sofosbuvir) are both used to treat hepatitis c. Based on Medicare Part D data, Harvoni costs $24,958.00 per claim, which is 5% less than Epclusa at $26,143.00 per claim.
Medicare spent $1.1B on Epclusa and $1.2B on Harvoni. In terms of patient reach, Harvoni serves more beneficiaries (12,000 vs 10,000).
Year-over-year spending changed -15.7% for Epclusa and -38.2% for Harvoni.
Epclusa has a generic available, while Harvoni remains brand-only until its patent expires Oct 10, 2030.
Frequently Asked Questions
Harvoni is cheaper at $24,958.00 per claim, compared to $26,143.00 for Epclusa. That makes Harvoni about 5% less expensive per claim based on Medicare Part D data.
Yes, both Epclusa and Harvoni are used to treat hepatitis c. Your doctor can help determine which medication is more appropriate for your specific situation.
Epclusa has a generic version (Sofosbuvir/Velpatasvir) available, which is typically much cheaper. Harvoni is currently brand-only, with patent expiring Oct 10, 2030.
Medicare Part D spent $1.1B on Epclusa covering 10,000 beneficiaries, and $1.2B on Harvoni covering 12,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.